Drug combo ups progression-free survival for metastatic prostate cancer
For patients with metastatic castration-resistant prostate cancer (mCRPC), talazoparib plus enzalutamide results in improvement in radiographic progression-free survival (rPFS), according to a study published online June ...
Jun 8, 2023
0
15